Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)
This study has been completed.
First Posted: September 27, 2012
Last Update Posted: January 14, 2016
Premier Research Group plc
Information provided by (Responsible Party):